Humana Inc. (NYSE:HUM) has been assigned a consensus recommendation of “Hold” from the twenty-four ratings firms that are currently covering the firm, Marketbeat reports. Thirteen equities research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $251.80.

A number of equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Humana from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Credit Suisse Group assumed coverage on shares of Humana in a report on Thursday, November 2nd. They set a “neutral” rating and a $256.00 target price for the company. BidaskClub raised shares of Humana from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. UBS AG reaffirmed a “neutral” rating and set a $250.00 target price (up previously from $237.00) on shares of Humana in a report on Wednesday, August 9th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $223.00 price target (up previously from $200.00) on shares of Humana in a research report on Thursday, August 3rd.

In other news, VP Timothy S. Huval sold 7,803 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the sale, the vice president now owns 8,831 shares of the company’s stock, valued at $2,279,634.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the sale, the insider now directly owns 18,042 shares in the company, valued at approximately $4,672,878. The disclosure for this sale can be found here. Insiders have sold 20,660 shares of company stock worth $5,319,600 in the last three months. Corporate insiders own 0.80% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Koch Industries Inc. purchased a new stake in shares of Humana during the second quarter worth approximately $404,000. Adviser Investments LLC purchased a new stake in shares of Humana during the third quarter worth approximately $635,000. Teachers Advisors LLC increased its stake in shares of Humana by 31.6% during the second quarter. Teachers Advisors LLC now owns 630,835 shares of the insurance provider’s stock worth $151,792,000 after buying an additional 151,603 shares during the period. Prisma Capital Partners LP purchased a new stake in shares of Humana during the second quarter worth approximately $7,122,000. Finally, Federated Investors Inc. PA increased its stake in shares of Humana by 608.1% during the second quarter. Federated Investors Inc. PA now owns 34,626 shares of the insurance provider’s stock worth $8,331,000 after buying an additional 29,736 shares during the period. Hedge funds and other institutional investors own 96.15% of the company’s stock.

Shares of Humana (NYSE:HUM) opened at $233.28 on Thursday. Humana has a 1-year low of $186.25 and a 1-year high of $264.56. The stock has a market cap of $34,223.56, a price-to-earnings ratio of 20.44, a PEG ratio of 1.65 and a beta of 0.91. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35.

Humana (NYSE:HUM) last released its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. During the same quarter in the prior year, the firm earned $3.18 earnings per share. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. equities research analysts forecast that Humana will post 11.63 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.69%. Humana’s dividend payout ratio is presently 12.59%.

ILLEGAL ACTIVITY WARNING: “Humana Inc. (HUM) Given Average Rating of “Hold” by Brokerages” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/16/humana-inc-hum-given-average-rating-of-hold-by-brokerages.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.